The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Gillian GiffordRobert Brown

Abstract

Aberrant epigenetic regulation, such as CpG island methylation and associated transcriptional silencing of genes, has been implicated in a variety of human diseases, including cancer. Methylation of genes involved in apoptosis, including the DNA mismatch repair (MMR) gene hMLH1, can occur in tumor models of resistance to chemotherapeutic drugs. However, the relevance for acquired resistance to chemotherapy of patients' tumors remains unsubstantiated. Plasma DNA from cancer patients, including those with ovarian cancer, often contains identical DNA changes as the tumor and provides a means to monitor CpG island methylation changes. We have examined plasma DNA of patients with epithelial ovarian cancer enrolled in the SCOTROC1 Phase III clinical trial for methylation of the hMLH1 CpG island before carboplatin/taxoid chemotherapy and at relapse. Methylation of hMLH1 is increased at relapse, and 25% (34 of 138) of relapse samples have hMLH1 methylation that is not detected in matched prechemotherapy plasma samples. Furthermore, hMLH1 methylation is significantly associated with increased microsatellite instability in plasma DNA at relapse, providing an independent measure of function of the MMR pathway. Acquisition of hMLH1 methyla...Continue Reading

References

May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J RustinH E Lambert
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Dec 16, 1998·The American Journal of Surgical Pathology·H D Hoerl, W R Hart
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·D R DuckettP Modrich
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J MackayR Brown
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Apr 21, 2001·Blood·M ToyotaJ P Issa
Nov 21, 2002·Journal of the National Cancer Institute·Hsueh-Wei ChangIe-Ming Shih
Feb 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hideki ShimodairaJean Y J Wang
Apr 15, 2003·Nature Medicine·Toshiyasu TaniguchiAlan D D'Andrea
May 2, 2003·Annals of the New York Academy of Sciences·Susan H WeiTim H-M Huang
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Oct 3, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M BignamiP Karran

❮ Previous
Next ❯

Citations

Nov 30, 2006·Journal of Applied Genetics·Jaroslaw Paluszczak, Wanda Baer-Dubowska
May 17, 2008·HNO·P Schmezer, C Plass
May 16, 2013·Breast Cancer Research and Treatment·Dominique TwelvesClare M Isacke
Mar 20, 2013·Cell Biochemistry and Biophysics·Haleh Akhavan-Niaki, Ali Akbar Samadani
Jan 17, 2012·Cancer Letters·Brian S Gloss, Goli Samimi
Aug 25, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jinru ShiaDavid S Klimstra
Nov 19, 2005·Nature Reviews. Cancer·James M Allan, Lois B Travis
Jul 13, 2007·Nature Reviews. Cancer·Lloyd Kelland
Feb 8, 2008·Nature Reviews. Cancer·Thomas HelledayRicky A Sharma
Feb 24, 2010·Nature Reviews. Clinical Oncology·Madeleine HewishAlan Ashworth
Sep 6, 2011·Oncogene·L GalluzziG Kroemer
Oct 12, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M FlanaganR Brown
Oct 20, 2005·Journal of the National Cancer Institute·Frank Lyko, Robert Brown
Apr 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wei DaiRobert Brown
Dec 22, 2012·The Journal of Clinical Investigation·Roel G W VerhaakUNKNOWN Cancer Genome Atlas Research Network
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Constanze Zeller, Robert Brown
Aug 2, 2006·BMC Cancer·Jozien HellemanEls M J J Berns
Dec 17, 2008·Pharmacogenomics·Adam J W Paige, Robert Brown
Jun 4, 2008·Future Oncology·Sarah Blagden, Hani Gabra
May 19, 2010·Biomarkers in Medicine·Hirendra Nath Banerjee, Mukesh Verma
May 5, 2011·International Journal of Molecular Sciences·Mi Jeong Kwon, Young Kee Shin
Dec 4, 2012·International Journal of Molecular Sciences·Vladimir KashubaEugene Zabarovsky
Aug 5, 2006·Pharmacogenomics·Justin StebbingTim Crook
Jul 6, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E C GrendysT J Herzog
Sep 17, 2011·Cellular and Molecular Life Sciences : CMLS·Marieke A VolleberghSabine C Linn
Aug 19, 2011·Journal of Cancer Research and Clinical Oncology·Jin C KimYong S Kim
Mar 13, 2014·Critical Reviews in Clinical Laboratory Sciences·Søren KristiansenGyörgy Sölétormos
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Ladislav Novotny, Thomas Szekeres
Jul 16, 2015·International Journal of Cancer. Journal International Du Cancer·Norman HäfnerIngo B Runnebaum
Feb 3, 2016·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nicolette G AlkemaSteven de Jong
Nov 9, 2010·Gynecologic Oncology·Thomas E LiggettVictor Levenson
Aug 7, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Klaus JungAnja Rabien
Jul 22, 2010·Biochimica Et Biophysica Acta·Beate KöberleBernd Kaina
Oct 27, 2009·Gynecologic Oncology·Daniela E Matei, Kenneth P Nephew
Jan 27, 2009·Gynecologic Oncology·Jennifer E QuinnD Paul Harkin
Dec 17, 2008·The Journal of Molecular Diagnostics : JMD·Anatoliy MelnikovVictor Levenson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis